/
GOVX
$1.28-$0.04 (-3.03%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$6.9M
5M shares
52-week range
$0.96 – $24.50
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
252.24%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1806.22
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $963.0K | $1.2M | $1.8M | $385.5K | $81.5K | $0 | $4.0M | $2.5M |
| Cost of revenue | $1.9M | $0 | $0 | $0 | $9.1M | $20.7M | $95.4K | $0 |
| Gross profit | −$915.7K | $1.2M | $1.8M | $385.5K | −$9.0M | −$20.7M | $3.9M | $2.5M |
| Gross margin | -95.1% | 100.0% | 100.0% | 100.0% | -11090.9% | — | 97.6% | 100.0% |
| R&D | $1.9M | $1.9M | $2.4M | $15.6M | $9.1M | $20.7M | $23.7M | $18.1M |
| Operating income | −$2.6M | −$2.4M | −$2.8M | −$18.7M | −$14.0M | −$26.7M | −$25.1M | −$21.6M |
| EBITDA | −$2.5M | −$2.4M | −$2.8M | −$18.5M | −$14.0M | −$25.9M | −$24.9M | −$21.4M |
| Net income | −$2.6M | −$2.4M | −$3.0M | −$18.6M | −$14.0M | −$26.0M | −$25.0M | −$21.5M |
| Net margin | -265.8% | -201.6% | -162.2% | -4817.2% | -17198.3% | — | -632.0% | -862.3% |
| EPS (diluted) | -25.25 | -23.50 | -29.00 | -182.50 | -138.00 | -255.50 | -120.50 | -22.40 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-8.70 | $-12.64–$-4.74 | 2 |
| 2027 | $520M | $-3.07 | $-3.07–$-3.07 | 1 |
| 2028 | $225M | $-2.96 | $-2.96–$-2.96 | 1 |
| 2029 | $112M | $4.29 | $4.29–$4.29 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.71
Price
$1.28
Implied downside
-45%
Peer comparison
GeoVax Labs, Inc. New
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
www.geovax.com- Employees
- 19
- IPO / List date
- Feb 1, 1995
- HQ
- SMYRNA, GA
Held by traders on TradeandTell
No one on the platform currently holds GOVX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in GOVX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-01-12 | 1-for-25reverse |
| 2024-01-31 | 1-for-15reverse |
| 2020-09-25 | 1-for-20reverse |
| 2020-01-24 | 1-for-2000reverse |
| 2019-05-02 | 1-for-500reverse |
Recent trades on TradeandTell
No one on the platform has traded GOVX yet.
